Osteoarthritis endotype discovery via clustering of biochemical marker data

被引:85
作者
Angelini, Federico [1 ]
Widera, Pawel [1 ]
Mobasheri, Ali [2 ,3 ,4 ,5 ,6 ]
Blair, Joseph [7 ]
Struglics, Andre [8 ]
Uebelhoer, Melanie [9 ]
Henrotin, Yves [9 ,10 ]
Marijnissen, Anne Ca [4 ]
Kloppenburg, Margreet [11 ,12 ]
Blanco, Francisco J. [13 ]
Haugen, Ida K. [14 ]
Berenbaum, Francis [15 ]
Ladel, Christoph [16 ]
Larkin, Jonathan [17 ]
Bay-Jensen, Anne C. [7 ]
Bacardit, Jaume [1 ]
机构
[1] Newcastle Univ, Sch Comp, Newcastle Upon Tyne, Tyne & Wear, England
[2] Univ Oulu, Fac Med, Res Unit Med Imaging Phys & Technol, Oulu, Finland
[3] State Res Inst Ctr Innovat Med, Dept Regenerat Med, Vilnius, Lithuania
[4] UMC Utrecht, Rheumatol & Clin Immunol, Utrecht, Netherlands
[5] Sun Yat Sen Univ, Dept Joint Surg, Affiliated Hosp 1, Guangzhou, Peoples R China
[6] World Hlth Org Collaborating Ctr Publ Hlth Aspect, Liege, Belgium
[7] Nordic Biosci, ImmunoSci, Herlev, Denmark
[8] Lund Univ, Fac Med, Dept Clin Sci Lund, Orthopaed, Lund, Sweden
[9] Artialis SA, Liege, Belgium
[10] Univ Liege, Ctr Interdisciplinary Res Med CIRM, Liege, Belgium
[11] Leiden Univ, Rheumatol, Med Ctr, Leiden, Netherlands
[12] Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands
[13] Univ A Coruna, Serv Reumatol, INIBIC Hosp, La Coruna, Spain
[14] Diakonhjemmet Hosp, Div Rheumatol & Res, Oslo, Norway
[15] Sorbonne Univ, INSERM, Paris, France
[16] BioBone BV, Darmstadt, Germany
[17] GlaxoSmithKline USA, Philadelphia, PA USA
关键词
KNEE OSTEOARTHRITIS; GLOBAL BURDEN; DISEASE; INFLAMMATION; BIOMARKERS; PHENOTYPES; TURNOVER;
D O I
10.1136/annrheumdis-2021-221763
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Osteoarthritis (OA) patient stratification is an important challenge to design tailored treatments and drive drug development. Biochemical markers reflecting joint tissue turnover were measured in the IMI-APPROACH cohort at baseline and analysed using a machine learning approach in order to study OA-dominant phenotypes driven by the endotype-related clusters and discover the driving features and their disease-context meaning. Method Data quality assessment was performed to design appropriate data preprocessing techniques. The k-means clustering algorithm was used to find dominant subgroups of patients based on the biochemical markers data. Classification models were trained to predict cluster membership, and Explainable AI techniques were used to interpret these to reveal the driving factors behind each cluster and identify phenotypes. Statistical analysis was performed to compare differences between clusters with respect to other markers in the IMI-APPROACH cohort and the longitudinal disease progression. Results Three dominant endotypes were found, associated with three phenotypes: C1) low tissue turnover (low repair and articular cartilage/subchondral bone turnover), C2) structural damage (high bone formation/resorption, cartilage degradation) and C3) systemic inflammation (joint tissue degradation, inflammation, cartilage degradation). The method achieved consistent results in the FNIH/OAI cohort. C1 had the highest proportion of non-progressors. C2 was mostly linked to longitudinal structural progression, and C3 was linked to sustained or progressive pain. Conclusions This work supports the existence of differential phenotypes in OA. The biomarker approach could potentially drive stratification for OA clinical trials and contribute to precision medicine strategies for OA progression in the future.
引用
收藏
页码:666 / 675
页数:10
相关论文
共 55 条
[11]   Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature [J].
Dell'Isola, A. ;
Allan, R. ;
Smith, S. L. ;
Marreiros, S. S. P. ;
Steultjens, M. .
BMC MUSCULOSKELETAL DISORDERS, 2016, 17 :1-12
[12]  
Deveza LA, 2019, CLIN EXP RHEUMATOL, V37, P64
[13]   Is osteoarthritis one disease or a collection of many? [J].
Deveza, Leticia A. ;
Loeser, Richard F. .
RHEUMATOLOGY, 2018, 57 :34-42
[14]   Is osteoarthritis a heterogeneous disease that can be stratified into subsets? [J].
Driban, Jeffrey B. ;
Sitler, Michael R. ;
Barbe, Mary F. ;
Balasubramanian, Easwaran .
CLINICAL RHEUMATOLOGY, 2010, 29 (02) :123-131
[15]   Repeat Analysis and Incurred Sample Reanalysis: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team [J].
Fluhler, Eric ;
Vazvaei, Faye ;
Singhal, Puran ;
Vinck, Petra ;
Li, Wenkui ;
Bhatt, Jignesh ;
de Boer, Theo ;
Chaudhary, Ajai ;
Tangiuchi, Masahiro ;
Rezende, Vinicius ;
Zhong, Dafang .
AAPS JOURNAL, 2014, 16 (06) :1167-1174
[16]   Prospects for Therapies in Osteoarthritis [J].
Ghouri, Asim ;
Conaghan, Philip G. .
CALCIFIED TISSUE INTERNATIONAL, 2021, 109 (03) :339-350
[17]   Potential diagnostic value of a type X collagen neo-epitope biomarker for knee osteoarthritis [J].
He, Y. ;
Manon-Jensen, T. ;
Arendt-Nielsen, L. ;
Petersen, K. K. ;
Christiansen, T. ;
Samuels, J. ;
Abramson, S. ;
Karsdal, M. A. ;
Attur, M. ;
Bay-Jensen, A. C. .
OSTEOARTHRITIS AND CARTILAGE, 2019, 27 (04) :611-620
[18]   Alpha C-Telopeptide of Type I Collagen Is Associated With Subchondral Bone Turnover and Predicts Progression of Joint Space Narrowing and Osteophytes in Osteoarthritis [J].
Huebner, Janet L. ;
Bay-Jensen, Anne C. ;
Huffman, Kim M. ;
He, Yi ;
Leeming, Diana J. ;
McDaniel, Gary E. ;
Karsdal, Morten A. ;
Kraus, Virginia B. .
ARTHRITIS & RHEUMATOLOGY, 2014, 66 (09) :2440-2449
[19]   Osteoarthritis in 2020 and beyond: a Lancet Commission [J].
Hunter, David J. ;
March, Lyn ;
Chew, Mabel .
LANCET, 2020, 396 (10264) :1711-1712
[20]   Osteoarthritis [J].
Hunter, David J. ;
Bierma-Zeinstra, Sita .
LANCET, 2019, 393 (10182) :1745-1759